EHA 2022 | MYLOX-1: Phase IIa study of GB2064, an oral LOXL-2 inhibitor in myelofibrosis
Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares her excitement for the recently launched MYLOX-1 study (NCT04679870) which is looking at the impact of LOXL-2 inhibition in patients with myelofibrosis (MF). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Transcript (edited for clarity)
The MYLOX-1 study was presented as a trials-in-progress poster at the EHA meeting 2022. It’s a super exciting study, but there’s no results to date. The study will be fully accrued shortly and it’ll be really interesting as a kind of first-in-class, looking at LOXL inhibition and its ability to alter the bone marrow microenvironment and improve hematopoiesis for patients with myelofibrosis...
The MYLOX-1 study was presented as a trials-in-progress poster at the EHA meeting 2022. It’s a super exciting study, but there’s no results to date. The study will be fully accrued shortly and it’ll be really interesting as a kind of first-in-class, looking at LOXL inhibition and its ability to alter the bone marrow microenvironment and improve hematopoiesis for patients with myelofibrosis. For me, it’s really exciting because it reflects a novel mode of therapy, probably not very toxic, likely to be well tolerated and therefore easy to put in a combination. So I was super excited to see that data and will be looking for results as they become available.
Read more...
Disclosures
Research funding: Celgene, Constellation, Novartis
Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
